Abstract
Background: Insulin-like growth factor 1 (IGF-1) is a mitogenic hormone involved in many processes such as growth, metabolism, angiogenesis and differentiation. After very preterm birth, energy demands increase while maternal supplies of nutrients and other factors are lost and the infant may become dependent on parenteral nutrition for weeks. Low postnatal IGF-1 concentrations in preterm infants are associated with poor weight gain, retinopathy of prematurity (ROP) and other morbidities. We will describe the process by which we aim to develop supplementation with recombinant human (rh) IGF-1 and its binding protein rhIGFBP-3 as a possible therapy to promote growth and maturation and reduce morbidities in extremely preterm infants.
Methods: In order to calculate a dose of IGF-1 tolerated by neonates, a pharmacokinetic study of transfusion with fresh frozen plasma was performed, which provided a relatively low dose of IGF-1, (on average 1.4 µg/kg), that increased serum IGF-1 to levels close to those observed in fetuses and preterm infants of similar GAs. Thereafter, a Phase I 3 hours IV infusion of rhIGF-1/rhIGFBP-3 was conducted in 5 infants, followed by a Phase II study with four sections (A-D). In the Phase II, sections A-D studies, time on infusion increased and younger gestational ages were included. Results: IV infusion increased IGF-1 but with short half-life (0.5h) implying a need for continuous infusion. In order to obtain in utero levels of IGF-I, the dose was increased from 100 to 250 µg/kg/24 h and the infusion was prolonged from 3 weeks postnatal age until a postmenstrual age of 29 weeks and 6 days. Conclusion: The purpose has been to ensure high-quality research into the development of a new drug for preterm infants. We hope that our work will help to establish a new standard for the testing of medications for preterm infants.Keywords: Preterm infant, IGF-1, pharmacokinetic, drug development, preterm morbidity.
Current Pharmaceutical Design
Title:IGF-1 as a Drug for Preterm Infants: A Step-Wise Clinical Development
Volume: 23 Issue: 38
Author(s): Ann Hellstrom*, David Ley, Boubou Hallberg, Chatarina Lofqvist, Ingrid Hansen-Pupp, Luca A. Ramenghi, Jan Borg, Lois E. H. Smith and Anna-Lena Hard
Affiliation:
- Department of Ophthalmology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg,Sweden
Keywords: Preterm infant, IGF-1, pharmacokinetic, drug development, preterm morbidity.
Abstract: Background: Insulin-like growth factor 1 (IGF-1) is a mitogenic hormone involved in many processes such as growth, metabolism, angiogenesis and differentiation. After very preterm birth, energy demands increase while maternal supplies of nutrients and other factors are lost and the infant may become dependent on parenteral nutrition for weeks. Low postnatal IGF-1 concentrations in preterm infants are associated with poor weight gain, retinopathy of prematurity (ROP) and other morbidities. We will describe the process by which we aim to develop supplementation with recombinant human (rh) IGF-1 and its binding protein rhIGFBP-3 as a possible therapy to promote growth and maturation and reduce morbidities in extremely preterm infants.
Methods: In order to calculate a dose of IGF-1 tolerated by neonates, a pharmacokinetic study of transfusion with fresh frozen plasma was performed, which provided a relatively low dose of IGF-1, (on average 1.4 µg/kg), that increased serum IGF-1 to levels close to those observed in fetuses and preterm infants of similar GAs. Thereafter, a Phase I 3 hours IV infusion of rhIGF-1/rhIGFBP-3 was conducted in 5 infants, followed by a Phase II study with four sections (A-D). In the Phase II, sections A-D studies, time on infusion increased and younger gestational ages were included. Results: IV infusion increased IGF-1 but with short half-life (0.5h) implying a need for continuous infusion. In order to obtain in utero levels of IGF-I, the dose was increased from 100 to 250 µg/kg/24 h and the infusion was prolonged from 3 weeks postnatal age until a postmenstrual age of 29 weeks and 6 days. Conclusion: The purpose has been to ensure high-quality research into the development of a new drug for preterm infants. We hope that our work will help to establish a new standard for the testing of medications for preterm infants.Export Options
About this article
Cite this article as:
Hellstrom Ann*, Ley David, Hallberg Boubou, Lofqvist Chatarina, Hansen-Pupp Ingrid, Ramenghi A. Luca, Borg Jan, Smith E. H. Lois and Hard Anna-Lena, IGF-1 as a Drug for Preterm Infants: A Step-Wise Clinical Development, Current Pharmaceutical Design 2017; 23 (38) . https://dx.doi.org/10.2174/1381612823666171002114545
DOI https://dx.doi.org/10.2174/1381612823666171002114545 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficacy of BAINS Circuit in Treating Critically Ill Hypoxemic COVID-19
Patients During the Second Wave of the Pandemic in India
Reviews on Recent Clinical Trials Cytotoxicity of Aβ 1-42, RAGE23-54, and An Aβ -RAGE Complex in PC-12 Cells
Current Alzheimer Research Deciphering Dual Antiplatelet Therapy in the Era of Drug-Eluting Coronary Stents
Current Drug Targets Gastrointestinal Immune System and Brain Dialogue Implicated in Neuroinflammatory and Neurodegenerative Diseases
Current Molecular Medicine MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology Liraglutide Exerts Potential Anti-inflammatory Effect in Type 1 Diabetes by Inhibiting IFN-γ Production <I>via</I> Suppressing JAK-STAT Pathway
Endocrine, Metabolic & Immune Disorders - Drug Targets Pathogenicity of the 1918 Pandemic Influenza Virus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Type 2 Diabetes Mellitus in Saudi Arabia: Major Challenges and Possible Solutions
Current Diabetes Reviews Why Does Obesity Increase the Risk for Cardiovascular Disease?
Current Pharmaceutical Design Regulation of Myometrial Smooth Muscle Functions
Current Pharmaceutical Design The Heart Metabolism: Pathophysiological Aspects in Ischaemia and Heart Failure
Current Pharmaceutical Design Nanocellulose and its Composites for Biomedical Applications
Current Medicinal Chemistry Personalizing HIV Therapeutics in Resource-Limited Rural Communities: Lessons Learned From the Use of New Tools in Africa
Current Pharmacogenomics and Personalized Medicine Blocking HIV-1 Vif Restores a Natural Mechanism of Intracellular Antiviral Defense
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Physical Therapy Modalities in Management of Fibromyalgia
Current Pharmaceutical Design Investigation of the Relationship among Cortisol, Pro-inflammatory Cytokines, and the Degradation of Tryptophan into Kynurenine in Patients with Major Depression and Suicidal Behavior
Current Topics in Medicinal Chemistry The Use of Specific Monoclonal Antibodies to Target Immunogenic Tumor Membrane Proteins in Patients with Recurrent Pancreatic and Colon Cancer
Current Drug Delivery Prader-Willi Syndrome: Obesity due to Genomic Imprinting
Current Genomics Potential Health Benefits of Passion Fruit Peel Flour
The Natural Products Journal Free Radical Attack on Cholesterol: Oxysterols as Markers of Oxidative Stress and as Bioactive Molecules
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)